Trial Profile
Phase I trial of a new formulation of AV 1142742 in patients with rheumatoid arthritis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jun 2012
Price :
$35
*
At a glance
- Drugs AV 1142742 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- 21 Jun 2012 Primary endpoint 'Drug-elimination-half-life' has been met, according to a Medigene media release.
- 21 Jun 2012 Primary endpoint 'Trough-drug-concentration' has been met, according to a Medigene media release.
- 21 Jun 2012 Primary endpoint 'Peak-drug-concentration' has been met, according to a Medigene media release.